

**Renalytix plc
("Renalytix" or the "Company")**

Partnership with MVP Health Care

kidneyintelX.dkd now accessible for MVP's 700,000 members

LONDON and NEW YORK, 17 July 2025 Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with [kidneyintelX.dkd](#), the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, and [MVP Health Care](#) ("MVP"), a not-for-profit health insurer that provides services to 700,000 members in the northeastern part of the United States, have joined forces to mitigate the progression of chronic kidney disease in their insured type 2 diabetes patient population.

Through this partnership, MVP and Renalytix will collaborate with physician groups across MVP's network, with the goal of introducing and implementing *kidneyintelX.dkd* advanced risk assessment testing. The test, which accurately assesses patient-specific risk for progressive decline in kidney function, enables clinicians to target resources, therapeutic options, and care plans more appropriately, thereby increasing the chance for slowing disease progression and improving patient outcomes, including those associated with cardiovascular and metabolic comorbidities.

The *kidneyintelX.dkd* test, which is available to MVP's entire New York membership, is FDA approved and is recommended for use by KDIGO, the international kidney disease clinical guidelines.

Dr. Richard Dal Col, President of MVP Health Care, said: *"At MVP Health Care, we are committed to delivering innovative, affordable solutions that improve access to care and support better health for our members. This partnership with Renalytix reflects our mission to empower both providers and patients with the tools they need to make informed, proactive decisions about their health care journey. For our customers living with type 2 diabetes and CKD, this means earlier insights, more personalized support, and a better path forward."*

James McCullough, CEO of Renalytix, said: *"Forward-thinking in its approach, we're proud to partner with MVP Health Care as they bring all parties to the table to help solve the growing and costly CKD health epidemic. In healthcare systems, and with individual providers, where kidneyintelX.dkd is deployed, we are quantifiably mitigating CKD progression, while also demonstrating HEDIS-measure improvements in blood pressure control and HbA1c levels in high-risk patients."*

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)
Jeff Keating / David Hignell (Corporate Finance)
Vadim Alexandre (Corporate Broking)

Tel: +44 (0)20 3470 0470

Oberon Capital (Joint Broker)
Mike Seabrook / Nick Lovering

Tel: +44 (0)20 3179 5300

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled *in vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for *kidneyintelX.dkd* which is now offered commercially in the United States.

About MVP Health Care

MVP Health Care is a nationally recognized, not-for-profit health insurer caring for members in New York and Vermont. Committed to the complete well-being of the members and the communities it serves, MVP makes health insurance more convenient, more supportive, and more personal.

For more information visit www.mvphealthcare.com or on [Facebook](#), [Twitter](#), [Instagram](#), and [LinkedIn](#).

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDFQLLFEDLBBBK